GeneLancet Biosciences Inc. announces its receipt of additional grant support by NIH (R21).

DOYLESTWON, PA, January 31, 2024 – GeneLancet Biosciences Inc. (“GeneLancet “), an early-stage genome editing company, is pleased to announce its receipt of additional grant support by NIH (R21). The grant will support GeneLancet’s goal to eliminate HBV cccDNA, the major cause of chronic hepatitis B using its proprietary chemically ligated guide RNAs (LgRNA) in collaboration with Baruch S. Blumberg Institute.